

# Richard F Greil

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4531965/publications.pdf>

Version: 2024-02-01

624  
papers

32,792  
citations

6124

83  
h-index

7043

159  
g-index

638  
all docs

638  
docs citations

638  
times ranked

33515  
citing authors

#	ARTICLE	IF	CITATIONS
1	Transferring MINDACT to Daily Routine: Implementation of the 70-Gene Signature in Luminal Early Breast Cancer – Results from a Prospective Registry of the Austrian Group Medical Tumor Therapy (AGMT). <i>Breast Care</i> , 2022, 17, 1-9.	0.8	3
2	Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel. <i>Thrombosis and Haemostasis</i> , 2022, 122, 633-645.	1.8	7
3	Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 209-221.	4.6	233
4	A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 106-115.	3.2	18
5	Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1-5.	2.8	15
6	Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. <i>International Journal of Hematology</i> , 2022, 115, 222-232.	0.7	15
7	Detecting Bacterial – Human Lateral Gene Transfer in Chronic Lymphocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1094.	1.8	3
8	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 351-363.	13.9	278
9	Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort. <i>BMC Cancer</i> , 2022, 22, 51.	1.1	3
10	First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab & versus & chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. <i>Haematologica</i> , 2022, 107, 2108-2120.	1.7	53
11	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 282-293.	0.8	88
12	Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1404-1412.	1.3	25
13	Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 629-639.	13.9	243
14	Abstract P1-16-03: Response pattern to chemotherapy in metastatic breast cancer (MBC): Real-word data from the Austrian AGMT_MBC-Registry. <i>Cancer Research</i> , 2022, 82, P1-16-03-P1-16-03.	0.4	0
15	Abstract GS1-00: Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial. <i>Cancer Research</i> , 2022, 82, GS1-00-GS1-00.	0.4	9
16	Abstract PD10-06: Predictive value of RT-qPCR 27-gene IO score and comparison with RNA-Seq IO score in the NeoTRIPaPDL1 trial. <i>Cancer Research</i> , 2022, 82, PD10-06-PD10-06.	0.4	3
17	Abstract P2-07-12: Triple negative breast cancer subtypes and early dynamics of the 27-gene IO score predict pCR in the NeoTRIPaPDL1 trial. <i>Cancer Research</i> , 2022, 82, P2-07-12-P2-07-12.	0.4	4
18	Abstract P1-21-08: Brain metastases (BM) from breast cancer: Real-word data from the Austrian AGMT_MBC-registry. <i>Cancer Research</i> , 2022, 82, P1-21-08-P1-21-08.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Abstract P1-04-02: Immune milieu associated with PD-L1 status in TNBC is dependent on time of biomarker assessment and treatment received: A secondary analysis of the NeoTRIPaPDL1 trial. <i>Cancer Research</i> , 2022, 82, P1-04-02-P1-04-02.	0.4	0
20	Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. <i>Journal of Clinical Oncology</i> , 2022, 40, 2321-2332.	0.8	79
21	Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. <i>Oral Oncology</i> , 2022, 128, 105815.	0.8	17
22	Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy—A Retrospective Bi-Centric Cohort Study. <i>Cancers</i> , 2022, 14, 93.	1.7	7
23	Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents—A Prospective Cohort Study of the AGMT Study-Group. <i>Cancers</i> , 2022, 14, 2459.	1.7	4
24	The effect of exercise training on endothelial function in postmenopausal women with breast cancer under aromatase inhibitor therapy. <i>Cancer Medicine</i> , 2022, 11, 4946-4953.	1.3	2
25	Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 507-507.	0.8	15
26	Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC). <i>Journal of Clinical Oncology</i> , 2022, 40, 4141-4141.	0.8	3
27	Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. <i>Clinical Cancer Research</i> , 2022, 28, 4003-4017.	3.2	15
28	CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity. <i>Haematologica</i> , 2021, 106, 2102-2113.	1.7	22
29	Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. <i>Leukemia</i> , 2021, 35, 143-155.	3.3	52
30	RNA editing contributes to epitranscriptome diversity in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 1053-1063.	3.3	17
31	Reduced alpha diversity of the oral microbiome correlates with short progression-free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy (AGMT MM 1). <i>Tj ETQq10140.784334 rgBT</i>		
32	Olaratumab plus anthracycline in advanced/metastatic soft tissue sarcoma. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 21-25.	1.0	3
33	miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors. <i>Pharmaceuticals</i> , 2021, 14, 89.	1.7	9
34	Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110399.	1.4	1
35	Cytotoxic constituents and a new hydroxycinnamic acid derivative from <i>Leontodon saxatilis</i> (Asteraceae, Cichorieae). <i>RSC Advances</i> , 2021, 11, 10489-10496.	1.7	4
36	Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. <i>Lancet Haematology</i> , 2021, 8, e135-e148.	2.2	32

#	ARTICLE	IF	CITATIONS
37	Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies. <i>Cancers</i> , 2021, 13, 650.	1.7	4
38	Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients. <i>Future Science OA</i> , 2021, 7, FSO644.	0.9	2
39	Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy. <i>Supportive Care in Cancer</i> , 2021, 29, 5197-5207.	1.0	6
40	PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 223-234.	5.1	93
41	SAMHD1 restrains aberrant nucleotide insertions at repair junctions generated by DNA end joining. <i>Nucleic Acids Research</i> , 2021, 49, 2598-2608.	6.5	15
42	Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34. <i>British Journal of Cancer</i> , 2021, 124, 1795-1802.	2.9	3
43	Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). <i>Journal of Clinical Oncology</i> , 2021, 39, 1108-1118.	0.8	67
44	Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG) Tj ETQq0 0 0 rg212/Overlook 10 Tf 50	2.2	10
45	Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 906-909.	0.6	1
46	Results of a hospitalization policy of asymptomatic and pre-symptomatic COVID-19-positive long-term care facility residents in the province of Salzburg—a report from the AGMT COVID-19 Registry. <i>GeroScience</i> , 2021, 43, 1877-1897.	2.1	3
47	Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4981.	1.8	33
48	Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators. <i>Current Cancer Drug Targets</i> , 2021, 21, 353-359.	0.8	6
49	Two Cases of Pancytopenia with Coombs-Negative Hemolytic Anemia after Chimeric Antigen Receptor T-Cell Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5449.	1.8	3
50	Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16228-e16228.	0.8	2
51	Cytotoxic Compounds of Two Demosponges ( <i>Aplysina aerophoba</i> and <i>Spongia</i> sp.) from the Aegean Sea. <i>Biomolecules</i> , 2021, 11, 723.	1.8	3
52	Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. <i>Annals of Hematology</i> , 2021, 100, 1733-1742.	0.8	10
53	AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL. <i>Cancers</i> , 2021, 13, 2619.	1.7	5
54	PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , the, 2021, 8, e398-e409.	2.2	28

#	ARTICLE	IF	CITATIONS
55	CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues. <i>Blood</i> , 2021, 138, 1067-1080.	0.6	29
56	Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors. <i>Clinical Therapeutics</i> , 2021, 43, 1092-1111.	1.1	5
57	Evidence for Non-Cancer-Specific T Cell Exhaustion in the Tcl1 Mouse Model for Chronic Lymphocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6648.	1.8	1
58	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	7.7	79
59	Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 395-405.	13.9	82
60	Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. <i>European Journal of Cancer</i> , 2021, 151, 3-13.	1.3	29
61	Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial. <i>European Journal of Cancer</i> , 2021, 151, 201-210.	1.3	5
62	CAR T-Cell Therapy in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8996.	1.8	73
63	Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature. <i>ESMO Open</i> , 2021, 6, 100233.	2.0	4
64	The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8. <i>Clinical Cancer Research</i> , 2021, 27, 5931-5938.	3.2	1
65	Top 3 Abstracts concerning hormone-receptor-positive early breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 252-256.	0.3	1
66	A POLE Splice Site Deletion Detected in a Patient with Biclinal CLL and Prostate Cancer: A Case Report. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9410.	1.8	2
67	Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP. <i>Blood Advances</i> , 2021, 5, 2965-2968.	2.5	8
68	Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer. <i>Pancreatology</i> , 2021, 21, 1466-1471.	0.5	6
69	Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1131-1136.	1.0	4
70	The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9555.	1.8	3
71	Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110421.	0.8	4
72	Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy—A Review of the Literature. <i>Biomolecules</i> , 2021, 11, 1469.	1.8	9

#	ARTICLE	IF	CITATIONS
73	Leveraging immune memory against measles virus as an antitumor strategy in a preclinical model of aggressive squamous cell carcinoma. , 2021, 9, e002170.		3
74	Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6). Therapeutic Advances in Medical Oncology, 2021, 13, 17588359211042301.	1.4	1
75	Scalable Enrichment of Immunomodulatory Human Acute Myeloid Leukemia Cell Line-Derived Extracellular Vesicles. Cells, 2021, 10, 3321.	1.8	3
76	Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 183-183.	0.6	8
77	Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial. Blood, 2021, 138, 2459-2459.	0.6	0
78	Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study). Blood, 2021, 138, 1669-1669.	0.6	0
79	The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 1BA-1-1BA-1.	0.6	5
80	Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110423.	1.4	3
81	Kindlinâ€³ maintains marginal zone B cells but confines follicular B cell activation and differentiation. Journal of Leukocyte Biology, 2021, , .	1.5	3
82	Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry. Breast Cancer Research, 2021, 23, 112.	2.2	75
83	Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. Acta OncolÃ³gica, 2020, 59, 75-81.	0.8	10
84	Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. Leukemia and Lymphoma, 2020, 61, 377-386.	0.6	14
85	Lenalidomide maintenance for diffuse large Bâ€³cell lymphoma patients responding to Râ€³CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. British Journal of Haematology, 2020, 189, 84-96.	1.2	15
86	Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. Journal of Clinical Oncology, 2020, 38, 623-632.	0.8	73
87	Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30â€³positive aggressive lymphomas. European Journal of Haematology, 2020, 104, 251-258.	1.1	12
88	Efficacy and safety of tailored and doseâ€³dense adjuvant chemotherapy and trastuzumab for resected HER2â€³positive breast cancer: Results from the phase 3 PANTHER trial. Cancer, 2020, 126, 1175-1182.	2.0	14
89	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 2020, 382, 597-609.	13.9	789
90	Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy. Cancers, 2020, 12, 2812.	1.7	3

#	ARTICLE	IF	CITATIONS
91	A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha $\alpha$ 2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)â€”AGMT_CML 1. Hematological Oncology, 2020, 38, 792-798.	0.8	8
92	Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy. Journal of Clinical Medicine, 2020, 9, 2775.	1.0	10
93	Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). Oncoimmunology, 2020, 9, 1806680.	2.1	11
94	Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncology, The, 2020, 21, 1234-1243.	5.1	297
95	&lt;p&gt;Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options&lt;/p&gt;. Cancer Management and Research, 2020, Volume 12, 10615-10629.	0.9	11
96	IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?. British Journal of Haematology, 2020, 190, 314-317.	1.2	4
97	Comparison of high tone therapy and transcutaneous electrical nerve stimulation therapy in chemotherapy-induced polyneuropathy. Medicine (United States), 2020, 99, e20149.	0.4	4
98	RNA Editing Alters miRNA Function in Chronic Lymphocytic Leukemia. Cancers, 2020, 12, 1159.	1.7	11
99	The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial. European Journal of Cancer, 2020, 134, 99-106.	1.3	29
100	Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial. Journal of Clinical Medicine, 2020, 9, 1663.	1.0	7
101	Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptorâ€”positive Early Breast Cancer: Results from the ABCSG Trial 5. Clinical Cancer Research, 2020, 26, 5682-5688.	3.2	4
102	Prognostic Value of EndoPredict in Women with Hormone Receptorâ€”Positive, HER2-Negative Invasive Lobular Breast Cancer. Clinical Cancer Research, 2020, 26, 4682-4687.	3.2	22
103	Aâ€”multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in aâ€”real-life setting. Wiener Klinische Wochenschrift, 2020, 132, 415-422.	1.0	0
104	A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Haematologica, 2020, 105, e164-e168.	1.7	5
105	Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunity. Molecular Oncology, 2020, 14, 1930-1946.	2.1	21
106	Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group. Journal of Clinical Oncology, 2020, 38, 2839-2848.	0.8	28
107	Realâ€”world nonâ€”interventional longâ€”term postâ€”authorisation safety study of ruxolitinib in myelofibrosis. British Journal of Haematology, 2020, 191, 764-774.	1.2	20
108	Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network. Memo - Magazine of European Medical Oncology, 2020, 13, 27-31.	0.3	5

#	ARTICLE	IF	CITATIONS
109	Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2 <sup>+</sup> advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. <i>Breast</i> , 2020, 50, 64-70.	0.9	12
110	Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 Td ( Haematology, the, 2020, 7, e196-e208.	2.2	199
111	TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 2498-2502.	3.3	2
112	Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial. <i>European Journal of Cancer</i> , 2020, 127, 12-20.	1.3	26
113	Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 87-96.	1.1	6
114	Complete remission of disseminated Langerhans cell sarcoma after stem cell transplantation. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 102-105.	0.3	0
115	Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer Results from the AGMT GASTRIC-5 Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 935.	1.0	6
116	Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2856.	1.8	31
117	The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: <i>post hoc</i> analysis of an Austrian multicenter, noninterventional study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591990087.	1.4	33
118	Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34). <i>European Journal of Cancer</i> , 2020, 132, 43-52.	1.3	24
119	Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 37-38.	0.6	37
120	KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 6505-6505.	0.8	21
121	Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GE) cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4649-TPS4649.	0.8	5
122	Randomized Phase III Study of FOLFOX Alone and with Pegilodecakin as Second-line Therapy in Patients with Metastatic Pancreatic Cancer (SEQUOIA).. <i>Journal of Clinical Oncology</i> , 2020, 38, 637-637.	0.8	16
123	Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS261-TPS261.	0.8	20
124	Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer. <i>Oncology Letters</i> , 2020, 19, 1551-1558.	0.8	8
125	Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study). <i>Blood</i> , 2020, 136, 29-30.	0.6	0
126	Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial). <i>Blood</i> , 2020, 136, 27-29.	0.6	0

#	ARTICLE	IF	CITATIONS
127	The Integrin Adaptor Kindlin-3 Is Important for Development and Retention of Marginal Zone B Cells. <i>Blood</i> , 2020, 136, 46-47.	0.6	0
128	Phase II Single-Arm "Window-of-Opportunity" Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - First Results of the AGMT NHL15B Study. <i>Blood</i> , 2020, 136, 26-26.	0.6	0
129	Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma. <i>Future Oncology</i> , 2019, 15, 109-120.	1.1	39
130	Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade. <i>Journal of Clinical Medicine</i> , 2019, 8, 1014.	1.0	41
131	Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia. <i>Annals of Hematology</i> , 2019, 98, 2569-2578.	0.8	2
132	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 1915-1928.	6.3	1,804
133	Prevalence of comorbidity in cancer patients scheduled for systemic anticancer treatment in Austria. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 290-296.	0.3	5
134	Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study. <i>Targeted Oncology</i> , 2019, 14, 707-717.	1.7	15
135	Systemic treatment of metastatic breast cancer: SABCS 2018. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 253-256.	0.3	1
136	Positron Emission Tomographyâ€“Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. <i>Journal of Clinical Oncology</i> , 2019, 37, 2835-2845.	0.8	151
137	Treatment Algorithm for Patients With Gastric Adenocarcinoma: An Austrian Consensus on Systemic Therapy. <i>Anticancer Research</i> , 2019, 39, 4589-4596.	0.5	4
138	B-cellâ€“specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion. <i>Blood</i> , 2019, 134, 1717-1729.	0.6	17
139	Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. <i>Blood</i> , 2019, 134, 1608-1618.	0.6	85
140	Ixazomibâ€“Thalidomideâ€“Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. <i>British Journal of Cancer</i> , 2019, 121, 751-757.	2.9	17
141	Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987763.	1.4	5
142	Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics. <i>Annals of Oncology</i> , 2019, 30, 652-653.	0.6	15
143	Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR). <i>Breast Cancer Research</i> , 2019, 21, 19.	2.2	44
144	Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2019, 98, 2139-2150.	0.8	39

#	ARTICLE	IF	CITATIONS
145	Lignans and sesquiterpene lactones from <i>Hypochaeris radicata</i> subsp. <i>neapolitana</i> (Asteraceae.) Tj ETQq1 1 0.784314 rgBT /Qverlock 10	1.4	6
146	Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, 159-166.e3.	1.0	14
147	Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2 <sup>+</sup> Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. <i>Clinical Cancer Research</i> , 2019, 25, 3865-3872.	3.2	54
148	Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL <sup>®</sup> a mabtenance trial. <i>Cancer Medicine</i> , 2019, 8, 1401-1405.	1.3	7
149	HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1115.	1.8	144
150	Cytotoxic Properties of Damiana ( <i>Turnera diffusa</i> ) Extracts and Constituents and A Validated Quantitative UHPLC-DAD Assay. <i>Molecules</i> , 2019, 24, 855.	1.7	15
151	Intense Uptake of Liposomal Curcumin by Multiple Myeloma Cell Lines: Comparison to Normal Lymphocytes, Red Blood Cells and Chronic Lymphocytic Leukemia Cells. <i>Anticancer Research</i> , 2019, 39, 1161-1168.	0.5	10
152	Next Generation Sequencing in AML <sup>®</sup> On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?. <i>Cancers</i> , 2019, 11, 252.	1.7	44
153	Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL <sup>®</sup> and/or BIM. <i>European Journal of Haematology</i> , 2019, 102, 437-441.	1.1	18
154	Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSC-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 339-351.	5.1	167
155	C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival Prediction in Pancreatic Cancer Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 1791.	1.0	9
156	Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. <i>Blood</i> , 2019, 133, 840-851.	0.6	228
157	Pharmacokinetics of liposomal curcumin (Lipocurc <sup>®</sup> , <sup>®</sup> ) infusion: effect of co-medication in cancer patients and comparison with healthy individuals. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 265-275.	1.1	18
158	BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF- $\kappa$ B Nuclear Translocation. <i>Clinical Cancer Research</i> , 2019, 25, 1901-1912.	3.2	23
159	Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 43-56.	5.1	448
160	Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development. <i>Leukemia</i> , 2019, 33, 957-968.	3.3	22
161	Impact of Breast Surgery in Primary Metastasized Breast Cancer. <i>Annals of Surgery</i> , 2019, 269, 1163-1169.	2.1	130
162	Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial). <i>Blood</i> , 2019, 134, 343-343.	0.6	39

#	ARTICLE	IF	CITATIONS
163	Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. Journal of Clinical Oncology, 2019, 37, 6000-6000.	0.8	118
164	Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with <i>BRAF</i> V600E-mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial.. Journal of Clinical Oncology, 2019, 37, 187-187.	0.8	66
165	A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.. Journal of Clinical Oncology, 2019, 37, 3537-3537.	0.8	0
166	Mouse models to decipher anti-tumor immunity. Oncotarget, 2019, 10, 5005-5006.	0.8	0
167	Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1-RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSC). Blood, 2019, 134, 2740-2740.	0.6	0
168	Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial. Blood, 2019, 134, 1547-1547.	0.6	10
169	Nonmetastatic pancreatic cancer. Strahlentherapie Und Onkologie, 2018, 194, 627-637.	1.0	4
170	Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes. Nature Communications, 2018, 9, 1219.	5.8	20
171	Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia. Wiener Klinische Wochenschrift, 2018, 130, 115-125.	1.0	0
172	The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe. Expert Review of Hematology, 2018, 11, 219-237.	1.0	28
173	Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia. Blood, 2018, 131, 1337-1349.	0.6	18
174	Imprecision and DNA Break Repair Biased towards Incompatible End Joining in Leukemia. Molecular Cancer Research, 2018, 16, 428-438.	1.5	11
175	Clonal evolution and heterogeneity in metastatic head and neck cancer—An analysis of the Austrian Study Group of Medical Tumour Therapy study group. European Journal of Cancer, 2018, 93, 69-78.	1.3	25
176	A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) — AGMT_CMML-1. Leukemia and Lymphoma, 2018, 59, 1121-1126.	0.6	5
177	Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). Leukemia and Lymphoma, 2018, 59, 1113-1120.	0.6	23
178	A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients. Supportive Care in Cancer, 2018, 26, 1345-1352.	1.0	7
179	Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group. Journal of Clinical Oncology, 2018, 36, 2603-2611.	0.8	7
180	Investigating epigenetic effects of activation-induced deaminase in chronic lymphocytic leukemia. PLoS ONE, 2018, 13, e0208753.	1.1	4

#	ARTICLE	IF	CITATIONS
181	Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters. PLoS ONE, 2018, 13, e0206688.	1.1	12
182	Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial. Cancer Medicine, 2018, 7, 5962-5972.	1.3	23
183	Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial). BMC Cancer, 2018, 18, 1074.	1.1	12
184	ASCO 2018 highlights: metastatic breast cancer. Memo - Magazine of European Medical Oncology, 2018, 11, 276-279.	0.3	14
185	Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype. World Neurosurgery, 2018, 120, 442-447.	0.7	9
186	SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis. Memo - Magazine of European Medical Oncology, 2018, 11, 208-212.	0.3	5
187	Cure in metastatic breast cancer. Memo - Magazine of European Medical Oncology, 2018, 11, 172-179.	0.3	23
188	DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer. Theranostics, 2018, 8, 2278-2288.	4.6	28
189	A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurcâ,ç) in patients with locally advanced or metastatic cancer. Cancer Chemotherapy and Pharmacology, 2018, 82, 695-706.	1.1	76
190	Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft MedikamentÄtse Tumortherapie). BMC Cancer, 2018, 18, 11.	1.1	14
191	Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemiaâ€”results of the AMLSG 11-08 trial. Leukemia, 2018, 32, 1621-1630.	3.3	81
192	Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer. Oncotarget, 2018, 9, 16512-16520.	0.8	71
193	Remission maintenance treatment options in chronic lymphocytic leukemia. Cancer Treatment Reviews, 2018, 70, 56-66.	3.4	2
194	Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. Annals of Hematology, 2018, 97, 1825-1839.	0.8	6
195	TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia. Oncoimmunology, 2018, 7, e1371399.	2.1	55
196	Long-Term Efficacy and Safety of Ropoginterferon Alfa-2b in Patients with Polycythemia Vera â€” Final Phase I/II Pegivera Study Results. Blood, 2018, 132, 3030-3030.	0.6	12
197	Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.. Journal of Clinical Oncology, 2018, 36, 500-500.	0.8	23
198	Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study.. Journal of Clinical Oncology, 2018, 36, 538-538.	0.8	1

#	ARTICLE	IF	CITATIONS
199	Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial).. Journal of Clinical Oncology, 2018, 36, 7515-7515.	0.8	17
200	Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations. Oncotarget, 2018, 9, 20928-20940.	0.8	6
201	Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia. Anticancer Research, 2018, 38, 121-130.	0.5	6
202	Risks and chances of aberrant DNA repair in cancer. Oncoscience, 2018, 5, 256-257.	0.9	0
203	Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer. Pharmacogenomics Journal, 2017, 17, 344-350.	0.9	10
204	Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib+dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study. Leukemia, 2017, 31, 997-1000.	3.3	64
205	Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncology, The, 2017, 18, 454-463.	5.1	78
206	Reactivation of dormant anti-tumor immunity – a clinical perspective of therapeutic immune checkpoint modulation. Cell Communication and Signaling, 2017, 15, 5.	2.7	34
207	SABCS 2016: systemic therapy for metastatic breast cancer. Memo - Magazine of European Medical Oncology, 2017, 10, 86-89.	0.3	8
208	Transient congenital dilated cardiomyopathy after maternal R-CHOP chemotherapy during pregnancy. Reproductive Toxicology, 2017, 71, 146-149.	1.3	12
209	The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation. Cell Communication and Signaling, 2017, 15, 13.	2.7	63
210	Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia. Wiener Klinische Wochenschrift, 2017, 129, 141-144.	1.0	3
211	A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. Blood, 2017, 129, 383-385.	0.6	51
212	PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet, The, 2017, 390, 2790-2802.	6.3	274
213	Improvement of quality of life and psychological distress after inpatient cancer rehabilitation. Wiener Klinische Wochenschrift, 2017, 129, 692-701.	1.0	28
214	Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial. Annals of Hematology, 2017, 96, 1155-1162.	0.8	6
215	Update on squamous cell carcinoma of the head and neck. Memo - Magazine of European Medical Oncology, 2017, 10, 220-223.	0.3	22
216	Antiangiogenic therapy in breast cancer. Memo - Magazine of European Medical Oncology, 2017, 10, 194-201.	0.3	8

#	ARTICLE	IF	CITATIONS
217	ASCO-update: gastrointestinal tumors. Memo - Magazine of European Medical Oncology, 2017, 10, 240-243.	0.3	0
218	The first meeting of the Austrian Expert Panel for Molecular Cancer Profiling. Memo - Magazine of European Medical Oncology, 2017, 10, 255-258.	0.3	0
219	Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. International Journal of Molecular Sciences, 2017, 18, 837.	1.8	19
220	Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group. International Journal of Molecular Sciences, 2017, 18, 415.	1.8	45
221	Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy. PLoS ONE, 2017, 12, e0180995.	1.1	15
222	Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma. HemaSphere, 2017, 1, e5.	1.2	18
223	Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Journal of Clinical Oncology, 2017, 35, 2473-2481.	0.8	148
224	Soluble CD87 (s-uPAR) predicts bevacizumab-based first line treatment of metastatic colorectal cancer (mCRC): Results from a prospective multi-center study.. Journal of Clinical Oncology, 2017, 35, 604-604.	0.8	1
225	Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence â€” A Phase II Study. Anticancer Research, 2017, 37, 2683-2691.	0.5	10
226	Distribution and Metabolism of Lipocurcâ„¢ (Liposomal Curcumin) in Dog and Human Blood Cells: Species Selectivity and Pharmacokinetic Relevance. Anticancer Research, 2017, 37, 3483-3492.	0.5	14
227	Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/ Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients â€” AGMT_GASTRIC-3. , 2017, 37, 5553-5558.		9
228	COSMOS: MOR208 plus idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (BTKi)â€”A two-cohort phase II study.. Journal of Clinical Oncology, 2017, 35, TPS7567-TPS7567.	0.8	0
229	miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites. International Journal of Molecular Sciences, 2016, 17, 156.	1.8	71
230	Panitumumab-Associated Encephalopathy after Accidental Intra-arterial Application through Dislocated Central Venous Access Device. Frontiers in Neurology, 2016, 7, 196.	1.1	1
231	Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesisâ€”Masters of Survival and Clonality?. International Journal of Molecular Sciences, 2016, 17, 1009.	1.8	39
232	The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma. Journal of Clinical Pathology, 2016, 69, 326-330.	1.0	15
233	Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration. Journal of Clinical Oncology, 2016, 34, 4329-4337.	0.8	70
234	Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood, 2016, 127, 2189-2192.	0.6	92

#	ARTICLE	IF	CITATIONS
235	Immune checkpoint blockade in ovarian cancer. Memo - Magazine of European Medical Oncology, 2016, 9, 82-84.	0.3	17
236	Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping. Journal of Clinical Oncology, 2016, 34, 2433-2434.	0.8	4
237	A Single Quantifiable Viral Load Is Predictive of Virological Failure in Human Immunodeficiency Virus (HIV)-Infected Patients on Combination Antiretroviral Therapy: The Austrian HIV Cohort Study. Open Forum Infectious Diseases, 2016, 3, ofw089.	0.4	16
238	Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncology, The, 2016, 17, 1230-1239.	5.1	55
239	The AKT 1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells. British Journal of Haematology, 2016, 172, 815-819.	1.2	8
240	CDK4/6 inhibition in luminal breast cancer. Memo - Magazine of European Medical Oncology, 2016, 9, 76-81.	0.3	8
241	Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the ACMT CLL-8a Mabtenance randomised trial. Lancet Haematology,the, 2016, 3, e317-e329.	2.2	42
242	Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. British Journal of Cancer, 2016, 115, 1215-1222.	2.9	15
243	NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients. British Journal of Cancer, 2016, 115, 1264-1272.	2.9	27
244	Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer. JAMA - Journal of the American Medical Association, 2016, 316, 1888.	3.8	79
245	T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. Journal of Hematology and Oncology, 2016, 9, 116.	6.9	201
246	Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. Journal of Hematology and Oncology, 2016, 9, 39.	6.9	36
247	An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide+â€‰dexamethasone for relapsed or relapsed/refractory multiple myeloma (RRâ€‰MM). American Journal of Hematology, 2016, 91, 806-811.	2.0	9
248	<i>DPYD</i> Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer. JAMA Oncology, 2016, 2, 655.	3.4	62
249	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of Oncology, 2016, 27, 417-423.	0.6	122
250	Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisoloneÂ compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma. European Journal of Cancer, 2016, 58, 112-121.	1.3	64
251	Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR). Leukemia and Lymphoma, 2016, 57, 2330-2341.	0.6	4
252	ILK Induction in Lymphoid Organs by a TNFÎ±â€‰NF-Î±Bâ€‰Regulated Pathway Promotes the Development of Chronic Lymphocytic Leukemia. Cancer Research, 2016, 76, 2186-2196.	0.4	13

#	ARTICLE	IF	CITATIONS
253	Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors. <i>Haematologica</i> , 2016, 101, e99-e102.	1.7	28
254	CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model. <i>Leukemia</i> , 2016, 30, 1409-1413.	3.3	15
255	Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: Final results of 116 patients treated in the international ACT-2 phase III trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7500-7500.	0.8	13
256	CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells. <i>Oncotarget</i> , 2016, 7, 49459-49469.	0.8	8
257	CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma. <i>Oncotarget</i> , 2016, 7, 78605-78618.	0.8	6
258	Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones. <i>Oncotarget</i> , 2016, 7, 51494-51502.	0.8	35
259	Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients. <i>Anticancer Research</i> , 2016, 36, 4715-4724.	0.5	5
260	Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Efficacy results of a phase II trial (AGMT MBC-6).. <i>Journal of Clinical Oncology</i> , 2016, 34, 1032-1032.	0.8	0
261	The fibrinogen/CRP ratio as a novel prognostic parameter for pancreatic cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15701-e15701.	0.8	0
262	CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylationâ€‘dependent and â€‘independent mechanisms. <i>British Journal of Haematology</i> , 2015, 169, 286-289.	1.2	26
263	Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5â€‘year followâ€‘up. <i>British Journal of Haematology</i> , 2015, 171, 344-354.	1.2	26
264	Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. <i>Blood</i> , 2015, 125, 1091-1097.	0.6	197
265	Ropeginterferon alfa-2b, a novel IFNÎ±-2b, induces high response rates with low toxicity in patients with polycythemia vera. <i>Blood</i> , 2015, 126, 1762-1769.	0.6	142
266	Response to comment by P. Vassilakopoulos and colleagues. <i>Haematologica</i> , 2015, 100, e482-e482.	1.7	1
267	Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1501-1508.	2.3	28
268	B cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T cell clonality in chronic lymphocytic leukemia. <i>Haematologica</i> , 2015, 100, e307-10.	1.7	10
269	The significance of pretreatment anemia in the era of Râ€‘ <i>sc</i> p>IPI</sc> and <sc>NCCN</sc>â€‘<sc>IPI</sc> prognostic risk assessment tools: a dualâ€‘center study in diffuse large Bâ€‘cell lymphoma patients. <i>European Journal of Haematology</i> , 2015, 95, 538-544.	1.1	29
270	CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer. <i>BMC Cancer</i> , 2015, 15, 725.	1.1	12

#	ARTICLE	IF	CITATIONS
271	Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer. <i>BMC Cancer</i> , 2015, 15, 996.	1.1	8
272	Cytomegalovirus reactivation and its clinical impact in patients with solid tumors. <i>Infectious Agents and Cancer</i> , 2015, 10, 45.	1.2	38
273	The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia. <i>Frontiers in Immunology</i> , 2015, 6, 177.	2.2	16
274	AID/APOBEC deaminases and cancer. <i>Oncoscience</i> , 2015, 2, 320-333.	0.9	105
275	The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. <i>British Journal of Cancer</i> , 2015, 112, 1405-1410.	2.9	68
276	Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. <i>Haematologica</i> , 2015, 100, 385-391.	1.7	26
277	Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2015, 386, 433-443.	6.3	444
278	Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with pegâ€prolineâ€interferon alphaâ€2b. <i>American Journal of Hematology</i> , 2015, 90, 288-294.	2.0	44
279	Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e143-e149.	0.2	1
280	Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction. <i>Leukemia Research</i> , 2015, 39, 296-306.	0.4	50
281	Digging deep into â€dirtyâ€drugs â€ modulation of the methylation machinery. <i>Drug Metabolism Reviews</i> , 2015, 47, 252-279.	1.5	63
282	Longitudinal analysis of 2293 NSCLC patients: A comprehensive study from the TYROL registry. <i>Lung Cancer</i> , 2015, 87, 193-200.	0.9	115
283	Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. <i>Lancet, The</i> , 2015, 385, 1418-1427.	6.3	154
284	IOERT as anticipated tumor bed boost during breastâ€conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancerâ€Results of a case series after 5â€year followâ€up. <i>International Journal of Cancer</i> , 2015, 136, 1193-1201.	2.3	32
285	A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation?. <i>Annals of Hematology</i> , 2015, 94, 345-346.	0.8	3
286	Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. <i>Annals of Oncology</i> , 2015, 26, 1685-1691.	0.6	108
287	Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics. <i>Leukemia and Lymphoma</i> , 2015, 56, 353-360.	0.6	3
288	Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. <i>Haematologica</i> , 2015, 100, 955-963.	1.7	75

#	ARTICLE	IF	CITATIONS
289	A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 409-422.	1.2	12
290	Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients. <i>Pharmacoeconomics</i> , 2015, 33, 179-190.	1.7	22
291	Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. <i>Journal of Pathology</i> , 2015, 236, 445-456.	2.1	49
292	VLA-4 and CXCR4 overexpression in bone marrow of an aleukemic B-cell acute lymphoblastic leukemia presenting with osteolytic bone lesions. <i>Leukemia and Lymphoma</i> , 2015, 56, 2465-2467.	0.6	4
293	A modified scoring of the NCCN IPI is more accurate in the elderly and is improved by albumin and $\Gamma_2$ microglobulin. <i>British Journal of Haematology</i> , 2015, 168, 239-245.	1.2	69
294	Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia. <i>Oncogene</i> , 2015, 34, 5341-5351.	2.6	51
295	Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model. <i>British Journal of Haematology</i> , 2015, 170, 515-522.	1.2	38
296	Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. <i>Annals of Oncology</i> , 2015, 26, 313-320.	0.6	251
297	Adipocyte-derived players in hematologic tumors: useful novel targets?. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 61-77.	1.4	13
298	Abstract P4-07-03: MicroRNAs correlating with outcome in patients treated with first-line bevacizumab for metastatic breast cancer. , 2015, , .		1
299	Abstract S2-06: Survival advantage of anastrozol compared to tamoxifen for lobular breast cancer in the ABCSG-8 study. , 2015, , .		14
300	Azacitidine in Acute Myeloid Leukemia with >30% Bone Marrow Blasts and <15 G/L White Blood Cell Count: Results from the Austrian Azacitidine Registry of the AGMT Study Group Versus Randomized Controlled Phase III Clinical Trial Data. <i>Blood</i> , 2015, 126, 2515-2515.	0.6	5
301	Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA+) According to the MRC Risk Index Score. <i>Blood</i> , 2015, 126, 2554-2554.	0.6	2
302	Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 2586-2586.	0.6	1
303	Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606). <i>Blood</i> , 2015, 126, 322-322.	0.6	32
304	Is It Time to Redefine Response in Elderly Patients with WHO-Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy?. <i>Blood</i> , 2015, 126, 3742-3742.	0.6	3
305	Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 504-504.	0.8	6
306	Influence of immunohistological detection of intratumoral urokinase-type plasminogen activator (uPA) on disease outcome in endocrine-treated postmenopausal patients with hormone receptor-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 551-551.	0.8	1

#	ARTICLE	IF	CITATIONS
307	CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21. <i>Oncotarget</i> , 2015, 6, 12048-12060.	0.8	18
308	Amphiregulin (AREG) expression and response to first-line panitumumab (pmab) plus FOLFIRI in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 731-731.	0.8	0
309	Abstract P6-08-47: Androgen receptor expression in pre-menopausal early breast cancer patients treated with endocrine therapy within the ABCSG-12 trial - a single center pilot analysis. , 2015, , .		0
310	Expression of amphiregulin (AREG) and response to first-line panitumumab (pmab) + FOLFIRI in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 3536-3536.	0.8	0
311	DYPD genotyping to predict toxicity in patients with stage III colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy in the PETACC-8 phase III trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3584-3584.	0.8	0
312	Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group. <i>Blood</i> , 2015, 126, 3941-3941.	0.6	0
313	Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial. <i>Anticancer Research</i> , 2015, 35, 517-21.	0.5	11
314	Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade. <i>Leukemia</i> , 2014, 28, 954-958.	3.3	29
315	Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1. <i>Modern Pathology</i> , 2014, 27, 906-915.	2.9	21
316	APOBEC3 signature mutations in chronic lymphocytic leukemia. <i>Leukemia</i> , 2014, 28, 1929-1932.	3.3	20
317	Bone-Targeted Therapy in Metastatic Breast Cancer - All Well-Established Knowledge?. <i>Breast Care</i> , 2014, 9, 323-330.	0.8	13
318	Liver toxicity during temozolomide chemotherapy caused by Chinese herbs. <i>BMC Complementary and Alternative Medicine</i> , 2014, 14, 115.	3.7	20
319	Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. <i>Annals of Oncology</i> , 2014, 25, 2378-2385.	0.6	93
320	The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1298-1305.	3.2	182
321	Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). <i>Annals of Oncology</i> , 2014, 25, 366-371.	0.6	62
322	Assessment of <sc>TP</sc>53 functionality in chronic lymphocytic leukaemia by different assays; an <sc>ERIC</sc>-wide approach. <i>British Journal of Haematology</i> , 2014, 167, 565-569.	1.2	7
323	Kasabach-Merritt phenomenon in hepatic angiosarcoma. <i>British Journal of Haematology</i> , 2014, 167, 716-718.	1.2	7
324	Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. <i>Leukemia Research</i> , 2014, 38, 475-483.	0.4	59

#	ARTICLE	IF	CITATIONS
325	Human immunodeficiency virus type 2 infections in Austria. Wiener Klinische Wochenschrift, 2014, 126, 212-216.	1.0	2
326	Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. Annals of Hematology, 2014, 93, 267-277.	0.8	17
327	Pleural decortication of a marginal zone lymphoma. Annals of Hematology, 2014, 93, 1253-1254.	0.8	0
328	Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells. Blood, 2014, 123, 2181-2188.	0.6	61
329	Multi-gene signatures in breast cancer: actual clinical impact. Memo - Magazine of European Medical Oncology, 2014, 7, 16-21.	0.3	1
330	Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. Annals of Hematology, 2014, 93, 459-462.	0.8	50
331	The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia. Annals of Hematology, 2014, 93, 361-374.	0.8	41
332	Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. Annals of Oncology, 2014, 25, 171-176.	0.6	48
333	Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood, 2014, 123, 985-991.	0.6	92
334	Alternative splice variants of AID are not stoichiometrically present at the protein level in chronic lymphocytic leukemia. European Journal of Immunology, 2014, 44, 2175-2187.	1.6	7
335	Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer, 2014, 111, 2051-2057.	2.9	26
336	The CXCR 4 and adhesion molecule expression of CD 34+ hematopoietic cells mobilized by <i>ex vivo</i> demand-driven addition of plerixafor to granulocyte colony-stimulating factor. Transfusion, 2014, 54, 2325-2335.	0.8	20
337	AID induces intraclonal diversity and genomic damage in CD86 + chronic lymphocytic leukemia cells. European Journal of Immunology, 2014, 44, 3747-3757.	1.6	22
338	Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Annals of Oncology, 2014, 25, 339-345.	0.6	326
339	Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz. Journal of Antimicrobial Chemotherapy, 2014, 69, 1090-1097.	1.3	22
340	Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Annals of Hematology, 2014, 93, 1825-1838.	0.8	84
341	Smart Home Precipitator for Biomass Furnaces: Design Considerations on a Small-Scale Electrostatic Precipitator. IEEE Transactions on Industry Applications, 2014, 50, 2219-2224.	3.3	16
342	Overcoming Resistance Against HER2-Targeting Agents in Fifth-Line Therapy: Is There Still a Place for Bevacizumab in HER2+ Breast Cancer?. Clinical Breast Cancer, 2014, 14, e17-e20.	1.1	3

#	ARTICLE	IF	CITATIONS
343	Malignant Lymphoblasts in T Cell Acute Lymphoblastic Leukemia Express High Levels of Kv1.3. <i>Biophysical Journal</i> , 2014, 106, 551a.	0.2	1
344	C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPi score in diffuse large B-cell lymphoma patients. <i>British Journal of Cancer</i> , 2014, 111, 55-60.	2.9	48
345	MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. <i>Haematologica</i> , 2014, 99, 1285-1291.	1.7	2
346	Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia. <i>Haematologica</i> , 2014, 99, 67-69.	1.7	35
347	Performance Characteristics of the Cobas Ampliprep/Cobas Taqman V2.0 and the Abbott Realtime Hepatitis C Assays - Implications for Response-Guided Therapy in Genotype 1 Infections. <i>Antiviral Therapy</i> , 2014, 19, 449-454.	0.6	13
348	Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. <i>Blood</i> , 2014, 123, 4027-4036.	0.6	72
349	Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: A single institution retrospective review. <i>International Journal of Oncology</i> , 2014, 44, 319-326.	1.4	36
350	Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Maintenance Trial. <i>Blood</i> , 2014, 124, 20-20.	0.6	8
351	Azacitidine in Patients with Treatment-Related Acute Myeloid Leukemia: Retrospective Analysis of the Austrian Azacitidine Registry. <i>Blood</i> , 2014, 124, 2284-2284.	0.6	2
352	Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry. <i>Blood</i> , 2014, 124, 3681-3681.	0.6	3
353	Azacitidine in Patients with Acute Myeloid Leukemia: Assessing the Potential Negative Impact of Elevated Baseline White Blood Cell Count on Outcome. <i>Blood</i> , 2014, 124, 3683-3683.	0.6	1
354	Addition of Rituximab to BEACOPPescalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study.. <i>Blood</i> , 2014, 124, 500-500.	0.6	12
355	Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia : Retrospective Analysis of the Austrian Azacitidine Registry. <i>Blood</i> , 2014, 124, 943-943.	0.6	2
356	Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes. <i>Blood</i> , 2014, 124, 955-955.	0.6	26
357	Predicting local recurrence using PAM50 in postmenopausal endocrine responsive breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1008-1008.	0.8	5
358	Follicle stimulating hormone (FSH) as a surrogate parameter for the effectiveness of endocrine therapy with or without zoledronic acid in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 577-577.	0.8	4
359	Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 520-520.	0.8	1
360	Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives. <i>World Journal of Gastroenterology</i> , 2014, 20, 6102.	1.4	45

#	ARTICLE	IF	CITATIONS
361	A randomized, double-blind, placebo-controlled, multicenter, binational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.. Journal of Clinical Oncology, 2014, 32, TPS3658-TPS3658.	0.8	0
362	Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG). Blood, 2014, 124, 1254-1254.	0.6	0
363	The Transcription Factor IRF4 Is Crucial for CLL Progression and Regulates Survival and Proliferation in a Microenvironment Related Manner. Blood, 2014, 124, 1973-1973.	0.6	0
364	Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study. Blood, 2014, 124, 3177-3177.	0.6	0
365	Spliceosome Mediated RNA Trans-Splicing for Targeting Kappa+ B-Cell Neoplasms. Blood, 2014, 124, 3633-3633.	0.6	0
366	Clonal Evolution in Relapsed or Refractory Diffuse Large B Cell Lymphoma. Blood, 2014, 124, 77-77.	0.6	0
367	Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis. Anticancer Research, 2014, 34, 227-33.	0.5	27
368	Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial. Anticancer Research, 2014, 34, 6767-73.	0.5	27
369	Azacitidine in patients with WHO-defined AML " Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. Journal of Hematology and Oncology, 2013, 6, 32.	6.9	56
370	ASH 2012 update chronic lymphocytic leukemia"the best is yet to come. Memo - Magazine of European Medical Oncology, 2013, 6, 177-180.	0.3	1
371	What's new in Hodgkin's lymphoma: ASH 2012 and more. Memo - Magazine of European Medical Oncology, 2013, 6, 193-196.	0.3	1
372	Therapy with JAK 1/2 inhibitors for myelofibrosis. Memo - Magazine of European Medical Oncology, 2013, 6, 109-113.	0.3	0
373	Management of immunosuppression in the treatment of chronic lymphocytic leukemia. Memo - Magazine of European Medical Oncology, 2013, 6, 37-40.	0.3	1
374	Topical evening primrose oil for reduction of bortezomib-induced skin reactions. Annals of Hematology, 2013, 92, 995-996.	0.8	3
375	Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfectd patient. Annals of Hematology, 2013, 92, 1001-1002.	0.8	3
376	Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood, 2013, 121, 4769-4777.	0.6	162
377	Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma. Journal of Clinical Oncology, 2013, 31, 247-255.	0.8	69
378	Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer. Journal of Clinical Oncology, 2013, 31, 2870-2878.	0.8	151

#	ARTICLE	IF	CITATIONS
379	CD40-Mediated Activation of Chronic Lymphocytic Leukemia Cells Promotes Their CD44-Dependent Adhesion to Hyaluronan and Restricts CCL21-Induced Motility. <i>Cancer Research</i> , 2013, 73, 561-570.	0.4	34
380	Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report. <i>BMC Cancer</i> , 2013, 13, 618.	1.1	12
381	Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2013, 49, 352-359.	1.3	23
382	Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 29-37.	5.1	997
383	Viral infections and their management in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1602-1613.	0.6	32
384	Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. <i>Lancet Oncology</i> , The, 2013, 14, 125-133.	5.1	107
385	AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1719-1725.	0.8	247
386	The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. <i>British Journal of Cancer</i> , 2013, 109, 589-596.	2.9	57
387	Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial. <i>British Journal of Cancer</i> , 2013, 108, 1408-1414.	2.9	25
388	88. <i>Cytokine</i> , 2013, 63, 264.	1.4	1
389	Everolimus in Postmenopausal, Hormone Receptor-Positive Advanced Breast Cancer: Summary and Results of an Austrian Expert Panel Discussion. <i>Breast Care</i> , 2013, 8, 293-299.	0.8	15
390	Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. <i>Annals of Oncology</i> , 2013, 24, 2342-2349.	0.6	89
391	Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome. <i>Oncology Letters</i> , 2013, 6, 1756-1758.	0.8	1
392	Utility of PCR in Diagnosis of Invasive Fungal Infections: Real-Life Data from a Multicenter Study. <i>Journal of Clinical Microbiology</i> , 2013, 51, 863-868.	1.8	54
393	CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8. <i>Clinical Cancer Research</i> , 2013, 19, 500-507.	3.2	107
394	ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials. <i>Journal of Clinical Oncology</i> , 2013, 31, 1522-1529.	0.8	94
395	EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. <i>Annals of Oncology</i> , 2013, 24, 640-647.	0.6	170
396	Mimicking the microenvironment in chronic lymphocytic leukaemia " where does the journey go?. <i>British Journal of Haematology</i> , 2013, 160, 711-714.	1.2	24

#	ARTICLE	IF	CITATIONS
397	A case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17p. <i>European Journal of Haematology</i> , 2013, 90, 349-350.	1.1	4
398	Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 2586-2592.	0.8	296
399	The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. <i>British Journal of Cancer</i> , 2013, 109, 2959-2964.	2.9	288
400	The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1021-1033.	1.1	14
401	Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentöse Tumortherapie. <i>Haematologica</i> , 2013, 98, 264-268.	1.7	36
402	Neoadjuvant Chemotherapy and Targeted Therapy in Breast Cancer: Past, Present, and Future. <i>Journal of Oncology</i> , 2013, 2013, 1-12.	0.6	52
403	Pharmacodynamic Analysis Of The Inhibitory Potency Of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3-ITD Positive Acute Myeloid Leukemia In The Ongoing AMLSG 16-10 Trial. <i>Blood</i> , 2013, 122, 1283-1283.	0.6	3
404	Analysis Of Molecular Responses and Chromosomal Aberrations In Patients With Polycythemia Vera Treated With Peg-Proline-Interferon Alpha-2b (AOP2014/P1101) In The Peginvera Study. <i>Blood</i> , 2013, 122, 1589-1589.	0.6	1
405	Anti-CXCL12/SDF-1 Spiegelmer Nox-A12 Alone and In Combination With Bortezomib and Dexamethasone In Patients With Relapsed Multiple Myeloma: Results From A Phase IIa Study. <i>Blood</i> , 2013, 122, 1951-1951.	0.6	3
406	Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study. <i>Blood</i> , 2013, 122, 4046-4046.	0.6	6
407	Bevacizumab (BEV) continued beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV + chemotherapy (CT): Biomarker findings from ML18147.. <i>Journal of Clinical Oncology</i> , 2013, 31, 452-452.	0.8	4
408	Cobas Ampliprep/Cobas TaqMan HIV-1 v2.0 Assay: Consequences at the Cohort Level. <i>PLoS ONE</i> , 2013, 8, e74024.	1.1	12
409	Abstract 603: CAL-101 acts synergistic with arsenic trioxide in chronic lymphocytic leukemia by preventing p21 phosphorylation through AKT1.., 2013, , .		1
410	Chronic Lymphocytic Leukemia Cells With Trisomy 12 Home To The Bone Marrow In a CXCR4-Independent Manner and Are Prone To Proliferate In Vitro. <i>Blood</i> , 2013, 122, 870-870.	0.6	0
411	Early PK-Analysis Predicts Molecular Response In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib. <i>Blood</i> , 2013, 122, 1485-1485.	0.6	0
412	Immune Monitoring In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib. <i>Blood</i> , 2013, 122, 2731-2731.	0.6	0
413	Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention?. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 425-441.	1.4	10
414	Influence of the American ODAAC Statement on Austrian Bevacizumab Prescribing Practice for Metastatic Breast Cancer. <i>Oncologist</i> , 2012, 17, e13-e17.	1.9	7

#	ARTICLE	IF	CITATIONS
415	What paths are open for tackling increasing azole resistance in <i>Aspergillus</i> in the clinic?. Expert Review of Anti-Infective Therapy, 2012, 10, 1229-1231.	2.0	0
416	Canonical and Noncanonical Hedgehog/GLI Signaling in Hematological Malignancies. Vitamins and Hormones, 2012, 88, 25-54.	0.7	51
417	Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial. Journal of Antimicrobial Chemotherapy, 2012, 67, 685-690.	1.3	27
418	First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study. Journal of Clinical Oncology, 2012, 30, 921-929.	0.8	244
419	Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial. Journal of Clinical Oncology, 2012, 30, 907-913.	0.8	273
420	Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group. Journal of Clinical Oncology, 2012, 30, 722-728.	0.8	91
421	Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica, 2012, 97, 1431-1438.	1.7	96
422	Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet, The, 2012, 379, 1791-1799.	6.3	564
423	Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia. Leukemia, 2012, 26, 2508-2516.	3.3	21
424	LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases—a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial. BMC Cancer, 2012, 12, 144.	1.1	16
425	Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group. BMC Cancer, 2012, 12, 349.	1.1	12
426	Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. BMC Cancer, 2012, 12, 438.	1.1	30
427	Treating T-cell lymphoma: is there a light at the end of the tunnel?. Memo - Magazine of European Medical Oncology, 2012, 5, 174-177.	0.3	0
428	A 55-year-old woman with locally advanced rectal cancer and a resectable synchronous hepatic metastasis: a case report. Memo - Magazine of European Medical Oncology, 2012, 5, 273-276.	0.3	0
429	Novel treatment avenues for peripheral T-cell lymphomas. Expert Opinion on Drug Discovery, 2012, 7, 1149-1163.	2.5	4
430	Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target. Journal of Molecular Medicine, 2012, 90, 681-693.	1.7	36
431	Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: Open questions. Critical Reviews in Oncology/Hematology, 2012, 82, 370-377.	2.0	8
432	Prognostic Value of Number of Removed Lymph Nodes, Number of Involved Lymph Nodes, and Lymph Node Ratio in 7502 Breast Cancer Patients Enrolled onto Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSC). Annals of Surgical Oncology, 2012, 19, 1808-1817.	0.7	49

#	ARTICLE	IF	CITATIONS
433	First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 65-72.	1.2	79
434	AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV). <i>Blood</i> , 2012, 120, 175-175.	0.6	4
435	First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy. <i>Blood</i> , 2012, 120, 57-57.	0.6	5
436	Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).. <i>Journal of Clinical Oncology</i> , 2012, 30, CRA3503-CRA3503.	0.8	31
437	Lysine Residue at Position 22 of the AID Protein Regulates Its Class Switch Activity. <i>PLoS ONE</i> , 2012, 7, e30667.	1.1	3
438	Abstract 1108: Subtype specific expression of immune-modulating miR-155 and miR-146a in anaplastic large cell lymphoma. , 2012, , .		0
439	T Cell Exhaustion Contributes to Immune Evasion in Chronic Lymphocytic Leukaemia. <i>Blood</i> , 2012, 120, 1773-1773.	0.6	0
440	Raltegravir in pregnancy: a case series presentation. <i>International Journal of STD and AIDS</i> , 2011, 22, 358-360.	0.5	26
441	Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 4234-4242.	0.8	183
442	A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. <i>Clinical Cancer Research</i> , 2011, 17, 6012-6020.	3.2	597
443	Combination Therapy of Lapatinib and Capecitabine for ErbB2-Positive Metastatic or Locally Advanced Breast Cancer: Results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe. <i>Onkologie</i> , 2011, 34, 233-238.	1.1	8
444	Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. <i>Acta Oncologica</i> , 2011, 50, 630-635.	0.8	38
445	Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. <i>Lancet Oncology</i> , The, 2011, 12, 631-641.	5.1	427
446	Sentinel Node Biopsy After Primary Chemotherapy in Breast Cancer: A Note of Caution from Results of ABCSG-14. <i>Breast Journal</i> , 2011, 17, 230-238.	0.4	6
447	Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. <i>Leukemia</i> , 2011, 25, 1452-1458.	3.3	83
448	Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. <i>Journal of Neuro-Oncology</i> , 2011, 105, 613-620.	1.4	149
449	Preoperative Oxaliplatin, Capecitabine, and External Beam Radiotherapy in Patients with Newly Diagnosed, Primary Operable, cT3NxM0, Low Rectal Cancer. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 100-107.	1.0	23
450	Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 75-85.	2.0	31

#	ARTICLE	IF	CITATIONS
451	Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients. <i>Annals of Hematology</i> , 2011, 90, 1083-1091.	0.8	8
452	Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. <i>Cancer</i> , 2011, 117, 2163-2169.	2.0	51
453	Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2653-2659.	0.8	196
454	Complete Remission of Waldenström Macroglobulinemia With Azacitidine and Rituximab. <i>Journal of Clinical Oncology</i> , 2011, 29, e696-e698.	0.8	1
455	Infusion reactions to the chimeric EGFR inhibitor cetuximab—change to the fully human anti-EGFR monoclonal antibody panitumumab is safe. <i>Annals of Oncology</i> , 2011, 22, 486-487.	0.6	7
456	Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1127-1136.	1.9	27
457	Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 7828-7834.	3.2	13
458	Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. <i>Haematologica</i> , 2011, 96, 238-244.	1.7	57
459	Efficacy of Temozolimide after Previous Treatment with Sunitinib, Sorafenib or Everolimus in Advanced Renal Cell Cancer. <i>Oncology</i> , 2011, 80, 34-41.	0.9	4
460	Zoledronic acid for adjuvant use in patients with breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 333-349.	1.1	9
461	A new trisaccharide derivative from <i>Prenanthes purpurea</i> . <i>Journal of the Serbian Chemical Society</i> , 2011, 76, 841-845.	0.4	2
462	Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group. <i>Blood</i> , 2011, 118, 1715-1715.	0.6	2
463	Non-Pegylated Liposomal Encapsulated Doxorubicin Reduces Cardiotoxicity in 1st Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Final Results of a Randomized Trial. <i>Blood</i> , 2011, 118, 2676-2676.	0.6	6
464	A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results. <i>Blood</i> , 2011, 118, 292-292.	0.6	7
465	Differential Bone Marrow Homing Capacity of VLA-4 and CD38 High Expressing Chronic Lymphocytic Leukemia Cells. <i>PLoS ONE</i> , 2011, 6, e23758.	1.1	43
466	Abstract 2273: Validation of putative stem cell factor SOX2 as predictive marker in breast cancer — with overall poor prognosis. , 2011, , .		0
467	Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2010, 89, 273-282.	0.8	6
468	An uncommon cause of anaemia: Sheehan's syndrome. <i>Wiener Klinische Wochenschrift</i> , 2010, 122, 717-719.	1.0	4

#	ARTICLE	IF	CITATIONS
469	Inhibition of G1, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells. <i>Oncogene</i> , 2010, 29, 4885-4895.	2.6	63
470	Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value. <i>British Journal of Cancer</i> , 2010, 103, 1201-1208.	2.9	31
471	MicroRNAs as biomarkers for the diagnosis and prognosis of human cancer. <i>Journal of Nucleic Acids Investigation</i> , 2010, 1, 14.	0.5	1
472	Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2010, 363, 640-652.	13.9	824
473	Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK) and ALK <sup>+</sup> anaplastic large-cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 16228-16233.	3.3	108
474	Modifying Akt Signaling in B-Cell Chronic Lymphocytic Leukemia Cells. <i>Cancer Research</i> , 2010, 70, 7336-7344.	0.4	24
475	Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. <i>Annals of Oncology</i> , 2010, 21, 2410-2419.	0.6	21
476	Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia. <i>Cell Cycle</i> , 2010, 9, 2836-2840.	1.3	116
477	The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 531-536.	1.1	90
478	microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. <i>Blood</i> , 2010, 115, 4191-4197.	0.6	99
479	Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 4199-4206.	0.8	397
480	PLZF/ZBTB16, a glucocorticoid response gene in acute lymphoblastic leukemia, interferes with glucocorticoid-induced apoptosis. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010, 120, 218-227.	1.2	40
481	Light Chain-Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4635-4641.	0.8	133
482	Myelodysplastic Syndromes (MDS). , 2010, , 153-222.		4
483	Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab In Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairis AGMT CLL4/Roche ML18434 Study. <i>Blood</i> . 2010. 116. 1380-1380.	0.6	1
484	Essential Thrombocythemia (ET). , 2010, , 15-50.		0
485	Primary Myelofibrosis (PMF) [Previously Chronic Idiopathic Myelofibrosid (CIMF), Myelofibrosis with Myeloid Metaplasia (MMM), Agnogenic Myeloid Metaplasia (AMM)]. , 2010, , 81-116.		0
486	Clonal Bone Marrow Failure Overlap Syndromes. , 2010, , 281-288.		0

#	ARTICLE	IF	CITATIONS
487	Introduction to "Classical" Chronic Myeloproliferative Disorders (CMPDs) Molecular and Cellular Biology. , 2010, , 1-13.		0
488	Isocitrate Dehydrogenase Gene Mutations In Elderly Patients with Acute Myeloid Leukemia (AML) and Outcome After Treatment with All-Trans Retinoic Acid: A Study of the German-Austrian AML Study Group (AMSLG). Blood, 2010, 116, 101-101.	0.6	0
489	Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer. New England Journal of Medicine, 2009, 360, 679-691.	13.9	976
490	Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer. Journal of Clinical Oncology, 2009, 27, 2630-2637.	0.8	582
491	Low p27 Expression Predicts Early Relapse and Death in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients Receiving Adjuvant Tamoxifen Therapy. Clinical Cancer Research, 2009, 15, 5888-5894.	3.2	26
492	The Dark Side of the Moon – the Side Effects of Therapy in a Dynamic Era of Breast Cancer Management. Breast Care, 2009, 4, 144-147.	0.8	2
493	Vincristine, Idarubicin, Dexamethasone and Thalidomide in Scleromyxoedema. Acta Dermato-Venereologica, 2009, 89, 631-635.	0.6	12
494	Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3. Journal of Clinical Oncology, 2009, 27, 3117-3125.	0.8	437
495	Circulating B-Cell Chronic Lymphocytic Leukemia Cells Display Impaired Migration to Lymph Nodes and Bone Marrow. Cancer Research, 2009, 69, 3121-3130.	0.4	78
496	Maintaining Bone Density in Patients Undergoing Treatment for Breast Cancer: Is There an Adjuvant Benefit?. Clinical Breast Cancer, 2009, 9, S18-S27.	1.1	11
497	The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer. Breast Cancer Research and Treatment, 2009, 115, 373-380.	1.1	9
498	Bisphosphonates as adjuvant therapy for breast cancer. Current Breast Cancer Reports, 2009, 1, 54-63.	0.5	5
499	Hodgkin lymphoma in Tyrol – a population-based study. Annals of Hematology, 2009, 88, 449-456.	0.8	5
500	Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study. European Journal of Surgical Oncology, 2009, 35, 1048-1054.	0.5	36
501	The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells. Cancer Letters, 2009, 273, 127-139.	3.2	42
502	Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer. Clinical Cancer Research, 2009, 15, 1452-1459.	3.2	592
503	Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer. Oncology Research and Treatment, 2009, 32, 18-24.	0.8	11
504	Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nature Reviews Clinical Oncology, 2009, 6, 405-418.	12.5	129

#	ARTICLE	IF	CITATIONS
505	Difference in the Relative Distribution of CD4+ T-cell Subsets in B-CLL With Mutated and Unmutated Immunoglobulin (Ig) VH Genes. <i>Journal of Immunotherapy</i> , 2009, 32, 302-309.	1.2	30
506	Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals. <i>Antiviral Therapy</i> , 2009, 14, 1189-1193.	0.6	14
507	PKC $\zeta$ is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKC $\zeta$ as a therapeutic target in chronic lymphocytic leukemia. <i>Blood</i> , 2009, 113, 2791-2794.	0.6	84
508	Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. <i>Blood</i> , 2009, 113, 3435-3442.	0.6	213
509	Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). <i>Breast Cancer Research and Treatment</i> , 2008, 112, 203-213.	1.1	34
510	The potential risk of neoadjuvant chemotherapy in breast cancer patients—results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07). <i>Breast Cancer Research and Treatment</i> , 2008, 112, 309-316.	1.1	28
511	Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13. <i>Journal of Molecular Medicine</i> , 2008, 86, 541-552.	1.7	24
512	Differential diagnostic challenge of chronic neutrophilic leukemia in a patient with prolonged leukocytosis. <i>Journal of Hematopathology</i> , 2008, 1, 23-27.	0.2	7
513	Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. <i>Wiener Klinische Wochenschrift</i> , 2008, 120, 697-709.	1.0	9
514	Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabine in Elderly Patients with Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, 60-64.	1.0	28
515	Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. <i>Lancet Oncology</i> , The, 2008, 9, 840-849.	5.1	345
516	Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 1767-1774.	3.2	81
517	Tumour-immune cell interactions modulated by chemokines. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 269-290.	1.4	37
518	MDM2 SNP309 Is Associated With Poor Outcome in B-Cell Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 2252-2257.	0.8	81
519	Anemia Is a Significant Prognostic Factor in Local Relapse-Free Survival of Premenopausal Primary Breast Cancer Patients Receiving Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil Chemotherapy. <i>Clinical Cancer Research</i> , 2008, 14, 2082-2087.	3.2	28
520	Is Chemoendocrine Treatment without Alternative?. <i>Breast Care</i> , 2008, 3, 231-235.	0.8	2
521	A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. <i>Annals of Oncology</i> , 2008, 19, 871-876.	0.6	42
522	Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study. <i>Annals of Oncology</i> , 2008, 19, 1266-1270.	0.6	11

#	ARTICLE	IF	CITATIONS
523	SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a. <i>Blood</i> , 2008, 112, 2168-2168.	0.6	12
524	Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated Followed by 4 Cycles of BEACOPP Baseline with or without Radiotherapy in Patients in Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised HD12 Trial of the German Hodgkin Study Group (GHSG). <i>Blood</i> , 2008, 112, 1558-1558.	0.6	9
525	Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in the Chairos Study. <i>Blood</i> , 2008, 112, 3175-3175.	0.6	17
526	Dose-Intensified Combined Modality Treatment with 2 Cycles of BEACOPP Escalated Followed by 2 Cycles of ABVD and Involved Field Radiotherapy (IF-RT) Is Superior to 4 Cycles of ABVD and IFRT in Patients with Early Unfavourable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. <i>Blood</i> , 2008, 112, 367-367.	0.6	9
527	Extended Adjuvant Therapy With Anastrozole Among Postmenopausal Breast Cancer Patients: Results From the Randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1845-1853.	3.0	288
528	A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. <i>British Journal of Cancer</i> , 2007, 97, 1021-1027.	2.9	90
529	Pathologic Complete Response With Six Compared With Three Cycles of Neoadjuvant Epirubicin Plus Docetaxel and Granulocyte Colony-Stimulating Factor in Operable Breast Cancer: Results of ABCSG-14. <i>Journal of Clinical Oncology</i> , 2007, 25, 2012-2018.	0.8	83
530	Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 4217-4223.	0.8	258
531	A New Sesquiterpene Lactone Sulfate from <i>Reichardia gaditana</i> (Asteraceae). <i>Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences</i> , 2007, 62, 132-134.	0.3	11
532	Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer?. <i>Lancet Oncology</i> , 2007, 8, 189-190.	5.1	21
533	Fulvestrant (â€ˆFaslodexâ€™™) in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 105-112.	1.1	20
534	Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C. <i>Wiener Klinische Wochenschrift</i> , 2007, 119, 254-258.	1.0	10
535	Retreatment with Alemtuzumab after a First, Successful Alemtuzumab Treatment in B-CLL. <i>Blood</i> , 2007, 110, 4714-4714.	0.6	6
536	Diffuse large B-cell lymphoma as a second, clonally unrelated lymphoproliferative disease in a patient with IgM monoclonal gammopathy of undetermined significance (MGUS) and concomitant polycythemia vera rubra. <i>Leukemia and Lymphoma</i> , 2006, 47, 940-943.	0.6	4
537	Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: Case report and review of the literature. <i>Leukemia and Lymphoma</i> , 2006, 47, 1683-1685.	0.6	29
538	Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2006, 32, 377-389.	3.4	58
539	The Still Long and Winding Road to Neoadjuvant Systemic Therapy as the Standard of Care in Breast Cancer. <i>Breast Care</i> , 2006, 1, 352-357.	0.8	5
540	Klinische Praxis Aromataseinhibitoren: Upfront, Switch oder Extended?. <i>Breast Care</i> , 2006, 1, 37-43.	0.8	0

#	ARTICLE	IF	CITATIONS
541	Adjuvanter Einsatz von Trastuzumab (Herceptin <sup>®</sup> ) in der klinischen Praxis außerhalb von klinischen Studien. <i>Breast Care</i> , 2006, 1, 96-101.	0.8	0
542	Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. <i>Blood</i> , 2006, 108, 2950-2956.	0.6	31
543	Purine Antagonists for Chronic Lymphocytic Leukaemia. <i>The Cochrane Library</i> , 2006, , CD004270.	1.5	30
544	IL-4 inhibits the TNF- $\alpha$ induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF- $\alpha$ to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1228-1237.	2.0	35
545	Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia. <i>Cancer</i> , 2006, 107, 2408-2416.	2.0	41
546	A role of TRAIL in killing osteoblasts by myeloma cells. <i>FASEB Journal</i> , 2006, 20, 759-761.	0.2	42
547	HD12 Randomised Trial Comparing 8 Dose-Escalated Cycles of BEACOPP with 4 Escalated and 4 Baseline Cycles in Patients with Advanced Stage Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Lymphoma Study Group (GHSG), University of Cologne, D-50924 Cologne, Germany.. <i>Blood</i> , 2006, 108, 99-99.	0.6	8
548	Antiproliferative and Proapoptotic Effects of Akacid-Medical-Formulation on Hematologic Cell Lines.. <i>Blood</i> , 2006, 108, 4380-4380.	0.6	0
549	The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial. <i>Haematologica</i> , 2006, 91, 1291-3.	1.7	3
550	Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma. <i>British Journal of Haematology</i> , 2005, 131, 329-337.	1.2	7
551	Long-term results of dose density therapy in patients with aggressive lymphoma. <i>Annals of Hematology</i> , 2005, 84, 217-222.	0.8	6
552	Up-Regulation of Functional Chemokine Receptor CCR3 in Human Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2005, 11, 2459-2465.	3.2	89
553	1,10-Epoxyhypocretenolides from the Azorean Endemic <i>Leontodon rigens</i> (Asteraceae). <i>Letters in Organic Chemistry</i> , 2005, 2, 461-464.	0.2	8
554	Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. <i>Lancet</i> , The, 2005, 366, 455-462.	6.3	828
555	Polyacetylenes from the Apiaceae Vegetables Carrot, Celery, Fennel, Parsley, and Parsnip and Their Cytotoxic Activities. <i>Journal of Agricultural and Food Chemistry</i> , 2005, 53, 2518-2523.	2.4	223
556	Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin's Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG).. <i>Blood</i> , 2005, 106, 2673-2673.	0.6	24
557	Recent Interim Analysis of the HD11 Trial of the GHSG: Intensification of Chemotherapy and Reduction of Radiation Dose in Early Unfavorable Stage Hodgkin's Lymphoma.. <i>Blood</i> , 2005, 106, 816-816.	0.6	18
558	Expression Levels of CD38 in Tumor Cells and T-Cells Are of Prognostic Value in B-CLL.. <i>Blood</i> , 2005, 106, 1189-1189.	0.6	12

#	ARTICLE	IF	CITATIONS
559	Transendothelial Migration of Myeloma Cells Is Increased by Tumor Necrosis Factor (TNF)- $\alpha$ via TNF Receptor 2 and Autocrine Up-Regulation of MCP-1. <i>Clinical Cancer Research</i> , 2004, 10, 1901-1910.	3.2	73
560	Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. <i>Annals of Oncology</i> , 2004, 15, 276-282.	0.6	45
561	Normative data for functional assessment of cancer therapy General scale and its use for the interpretation of quality of life scores in cancer survivors. <i>Acta Oncologica</i> , 2004, 43, 153-160.	0.8	109
562	Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 year. <i>European Journal of Haematology</i> , 2004, 72, 381-389.	1.1	77
563	Is higher income and educational status associated with poorer outcome in patients with Hodgkin's disease?. <i>European Journal of Haematology</i> , 2004, 73, 318-324.	1.1	10
564	Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia. <i>Leukemia Research</i> , 2004, 28, 1043-1051.	0.4	33
565	Pegfilgrastim Supports Delivery of CHOP-R Chemotherapy Administered Every 14 Days: A Randomised Phase II Study. <i>Blood</i> , 2004, 104, 3311-3311.	0.6	8
566	Longer Failure-Free Survival Interval of Epstein-Barr Virus-Associated Classical Hodgkin's Lymphoma: A Single-Institution Study. <i>Modern Pathology</i> , 2003, 16, 566-573.	2.9	37
567	A randomized study comparing interferon (IFN)- $\alpha$ plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML). <i>Leukemia Research</i> , 2003, 27, 405-411.	0.4	26
568	Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools. <i>Journal of Leukocyte Biology</i> , 2003, 74, 311-330.	1.5	26
569	Tetrcarcin-induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2-independent pathway. <i>Blood</i> , 2003, 101, 4561-4568.	0.6	49
570	Tuning the Rheostat of the Myelopoietic System via Fas and TRAIL. <i>Critical Reviews in Immunology</i> , 2003, 23, 301-322.	1.0	17
571	Diffuse Large B-cell Lymphoma with Infiltration-Associated Peripheral Neuropathy and Paraneoplastic Myopathy with a Prolonged Course Over Seven Years. <i>Leukemia and Lymphoma</i> , 2002, 43, 1687-1690.	0.6	6
572	Intravascular large B-cell lymphoma with a fulminant clinical course: a case report with definite diagnosis post mortem. <i>Annals of Oncology</i> , 2002, 13, 1503-1506.	0.6	20
573	The impact of hemoglobin levels on fatigue and quality of life in cancer patients. <i>Annals of Oncology</i> , 2002, 13, 965-973.	0.6	128
574	The Role of Soluble CD23 in Distinguishing Stable and Progressive Forms of B-chronic Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 2002, 43, 549-554.	0.6	25
575	Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia. <i>Blood</i> , 2002, 99, 722-723.	0.6	14
576	Splenectomy versus medical treatment for idiopathic thrombocytopenic purpura. <i>American Journal of Surgery</i> , 2002, 184, 606-609.	0.9	29

#	ARTICLE	IF	CITATIONS
577	Rapidly Alternating COPP/ABV/IMEP Is Not Superior to Conventional Alternating COPP/ABVD in Combination With Extended-Field Radiotherapy in Intermediate-Stage Hodgkin's Lymphoma: Final Results of the German Hodgkin's Lymphoma Study Group Trial HD5. <i>Journal of Clinical Oncology</i> , 2002, 20, 476-484.	0.8	51
578	Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2002, 119, 965-969.	1.2	39
579	Stressful death of ALL tumor cells following treatment with the antitumor agent Tetrocarcin. <i>FASEB Journal</i> , 2002, 16, 1295-1297.	0.2	46
580	Multidimensional scaling as a tool for analysing quality of life data. <i>Quality of Life Research</i> , 2002, 11, 223-233.	1.5	36
581	Epstein-Barr virus-associated extranodal NK/T-cell lymphoma, nasal type of the hypopharynx, in a renal allograft recipient: Case report and review of literature. <i>Human Pathology</i> , 2001, 32, 1264-1268.	1.1	25
582	Low-Dose Radiation Is Sufficient for the Noninvolved Extended-Field Treatment in Favorable Early-Stage Hodgkin's Disease: Long-Term Results of a Randomized Trial of Radiotherapy Alone. <i>Journal of Clinical Oncology</i> , 2001, 19, 2905-2914.	0.8	114
583	Primary Gastrointestinal B-Cell Lymphoma - A Clinicopathological and Immunohistochemical Study of 61 Cases with an Evaluation of Prognostic Parameters. <i>Pathology Research and Practice</i> , 2001, 197, 385-393.	1.0	18
584	Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts. <i>Cell Death and Differentiation</i> , 2001, 8, 1014-1021.	5.0	62
585	Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. <i>FASEB Journal</i> , 2001, 15, 1613-1615.	0.2	175
586	Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis in CEM-C7H2 acute leukemia cells. <i>Cell Death and Differentiation</i> , 2000, 7, 834-842.	5.0	148
587	Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. <i>Blood</i> , 2000, 95, 610-618.	0.6	111
588	Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): An AASLC phase II trial. <i>Annals of Oncology</i> , 2000, 11, 993-998.	0.6	34
589	Analysis of Bcl-2 Protein Expression in Chronic Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2000, 113, 219-229.	0.4	44
590	Gastric cancer cell lines lack Fas ligand (FasL) expression but kill T cells via a FasL independent pathway Reply. <i>Gut</i> , 2000, 46, 738-740.	6.1	6
591	Comparison of Two Quality-of-Life Instruments for Cancer Patients: The Functional Assessment of Cancer Therapy-General and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. <i>Journal of Clinical Oncology</i> , 1999, 17, 2932-2932.	0.8	173
592	Synergistic action of protein kinase C $\delta$ and calcineurin is sufficient for Fas ligand expression and induction of a crmA-sensitive apoptosis pathway in Jurkat T cells. <i>European Journal of Immunology</i> , 1999, 29, 3549-3561.	1.6	49
593	Interferon- $\gamma$ for the treatment of elderly patients with chronic myeloid leukaemia. <i>Leukemia Research</i> , 1998, 22, 881-886.	0.4	17
594	Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity. <i>British Journal of Haematology</i> , 1998, 102, 1069-1080.	1.2	13

#	ARTICLE	IF	CITATIONS
595	Leg ulcers associated with long-term hydroxyurea therapy. <i>Journal of the American Academy of Dermatology</i> , 1998, 39, 372-374.	0.6	89
596	Prognosis and Management Strategies of Lymphatic Neoplasias in the Elderly. <i>Oncology</i> , 1998, 55, 189-217.	0.9	19
597	Prognosis and Management Strategies of Lymphatic Neoplasias in the Elderly. <i>Oncology</i> , 1998, 55, 265-275.	0.9	5
598	Urticaria Pigmentosa: A Clinical, Hematopathologic, and Serologic Study of 30 Adults. <i>American Journal of Clinical Pathology</i> , 1998, 109, 279-285.	0.4	66
599	Einsatz hämatopoetischer Wachstumsfaktoren in der Therapie hämatologischer und onkologischer Krankheiten. <i>Oncology Research and Treatment</i> , 1998, 21, 527-532.	0.8	2
600	On the Role and Significance of Fas (Apo-1/CD95) Ligand (FasL) Expression in Immune Privileged Tissues and Cancer Cells Using Multiple Myeloma as a Model*. <i>Leukemia and Lymphoma</i> , 1998, 31, 477-490.	0.6	28
601	Differential Sensitivity of CD4+ and CD8+ T Lymphocytes to the Killing Efficacy of Fas (Apo-1/CD95) Ligand+ Tumor Cells in B Chronic Lymphocytic Leukemia. <i>Blood</i> , 1998, 91, 4273-4281.	0.6	100
602	Differential Sensitivity of CD4+ and CD8+ T Lymphocytes to the Killing Efficacy of Fas (Apo-1/CD95) Ligand+ Tumor Cells in B Chronic Lymphocytic Leukemia. <i>Blood</i> , 1998, 91, 4273-4281.	0.6	3
603	The interleukin 1 $\beta$ -converting enzyme inhibitor CrmA prevents Apo1/Fas- but not glucocorticoid-induced poly(ADP-ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells. <i>FEBS Letters</i> , 1997, 402, 36-40.	1.3	35
604	Cytokine Priming of the Granulocyte Respiratory Burst in Myelodysplastic Syndromes. <i>Leukemia and Lymphoma</i> , 1997, 27, 137-143.	0.6	12
605	Constitutive Expression of Fas (Apo-1/CD95) Ligand on Multiple Myeloma Cells: A Potential Mechanism of Tumor-Induced Suppression of Immune Surveillance. <i>Blood</i> , 1997, 90, 12-20.	0.6	129
606	Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: Results of the austrian multicenter phase II study. <i>Leukemia Research</i> , 1997, 21, 75-80.	0.4	30
607	Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multi-center trial by the Austrian Working Group For Medical Tumor Therapy. <i>Annals of Hematology</i> , 1997, 75, 135-140.	0.8	23
608	Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status. <i>British Journal of Haematology</i> , 1997, 97, 418-428.	1.2	39
609	Constitutive Expression of Fas (Apo-1/CD95) Ligand on Multiple Myeloma Cells: A Potential Mechanism of Tumor-Induced Suppression of Immune Surveillance. <i>Blood</i> , 1997, 90, 12-20.	0.6	20
610	Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon- $\gamma$ . <i>European Journal of Immunology</i> , 1996, 26, 3119-3126.	1.6	70
611	Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies. , 1996, 65, 498-505.		23
612	2-Fluorodeoxycytidine (Gemcitabine) Induces Apoptosis in Myeloma Cell Lines Resistant to Steroids and 2-Chlorodeoxyadenosine (2CdA). <i>Stem Cells</i> , 1996, 14, 351-362.	1.4	22

#	ARTICLE	IF	CITATIONS
613	Necrotizing Vasculitis Associated with Hepatitis C Virus Infection: Successful Treatment of Vasculitis with Interferon-Alpha despite Persistence of Mixed Cryoglobulinemia. <i>Dermatology</i> , 1995, 191, 43-45.	0.9	17
614	Multimodal Therapy in Life-Threatening Cerebral Lupus erythematosus: The Benefit of Cerebrospinal Fluid Pheresis. <i>International Archives of Allergy and Immunology</i> , 1995, 107, 592-594.	0.9	7
615	Apoptosis and Therapy of Malignant Diseases of the Hematopoietic System. <i>International Archives of Allergy and Immunology</i> , 1994, 105, 368-373.	0.9	13
616	EXTENSIVE MENINGEAL INVOLVEMENT AS THE PRIMARY MANIFESTATION OF A SYSTEMIC SMALL LYMPHOCYTIC LYMPHOMA: FAVOURABLE OUTCOME AFTER NEURAXIAL IRRADIATION WITHOUT CHEMOTHERAPY. <i>British Journal of Haematology</i> , 1993, 83, 674-675.	1.2	1
617	A monoclonal antibody directed against the human intercellular adhesion molecule (ICAM-1) modulates the release of tumor necrosis factor- $\alpha$ , interferon- $\gamma$ and interleukin 1. <i>European Journal of Immunology</i> , 1990, 20, 2591-2596.	1.6	42
618	Immunohistological assessment of bone marrow biopsies from patients with hairy cell leukemia: Changes following treatment with alpha-2-interferon and deoxycoformycin. <i>Leukemia Research</i> , 1989, 13, 377-383.	0.4	19
619	IMMUNOHISTOLOGY FOR QUANTIFICATION OF NORMAL BONE MARROW LYMPHOCYTE SUBSETS. <i>British Journal of Haematology</i> , 1989, 73, 576-577.	1.2	25
620	abl oncogene expression in non-Hodgkin lymphomas: Correlation to histological differentiation and clinical status. <i>International Journal of Cancer</i> , 1988, 42, 529-538.	2.3	9
621	Importance of an 85 kDa membrane glycoprotein for a variety of cell-cell interactions. <i>Molecular Immunology</i> , 1988, 25, 1053-1061.	1.0	17
622	In situ quantification of T-cell subsets, NK-like cells and macrophages in hodgkin's disease: Quantity and quality of infiltration density depends on histopathological subtypes. <i>Blut</i> , 1986, 53, 49-58.	1.2	16
623	Growth fraction of tumour cells and infiltration density with natural killer-like (HNK1+) cells in non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 1986, 62, 293-300.	1.2	17
624	Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSCG). <i>Breast Care</i> , 0, , 1-9.	0.8	0